FIGURE 3

FIGURE 3

Oligo‐fucoidan exhibits anti‐lipid accumulation and anti‐HCC effect in CD36 transgenic fish model. A, The anti‐lipid accumulation effect of fucoidan in a 15‐day‐old CD36 transgenic fish model revealed by Oil Red staining from CD36 transgenic fish fed with 24% high fat diet without or with fucoidan. The statistical analysis revealed significant reduction of Oil Red staining from OF treatment, each dot represent 10 larvae. B, The anti‐lipid accumulation effect of fucoidan in a 15‐day‐old CD36 transgenic fish model revealed by LipidGreen staining from CD36 transgenic fish fed with 24% high fat diet without or with fucoidan. The statistical analysis revealed significant reduction of lipid‐green staining from OF treatment, each dot represents 1 larva. C, The anti‐HCC effect of oligo‐fucoidan in a 1‐month‐old CD36 transgenic fish model revealed by H&E staining. CD36 transgenic fish fed with 24% high fat diet without and with fucoidan. Statistical analysis of H&E stain revealed significant reduction of steatosis and HCC formation upon OF treatment. D, Oligo‐fucoidan reduced the protein levels of PCNA proliferation marker in hepatic tissues of CD36 transgenic zebrafish fed by high fat diet and OF. Statistical analysis of PCNA IHC stain revealed significant reduction of PCNA nuclear staining upon OF treatment. E, The gene expression profiles of the selected marker genes of lipogenesis, cholesterol synthesis, inflammation, ER stress, and cell proliferation of oligo‐fucoidan treatment in a 1‐month‐old CD36 transgenic fish model. Statistical significance was calculated by t‐test: *P < .05, ***P ≤ .001; ****P ≤ .0001.